249 related articles for article (PubMed ID: 22252842)
1. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
Sharma A; Koldovsky U; Xu S; Mick R; Roses R; Fitzpatrick E; Weinstein S; Nisenbaum H; Levine BL; Fox K; Zhang P; Koski G; Czerniecki BJ
Cancer; 2012 Sep; 118(17):4354-62. PubMed ID: 22252842
[TBL] [Abstract][Full Text] [Related]
2. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.
Fracol M; Xu S; Mick R; Fitzpatrick E; Nisenbaum H; Roses R; Fisher C; Tchou J; Fox K; Zhang P; Czerniecki BJ
Ann Surg Oncol; 2013 Oct; 20(10):3233-9. PubMed ID: 23851609
[TBL] [Abstract][Full Text] [Related]
3. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
4. Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines.
Bahl S; Roses RE; Sharma A; Koldovsky U; Xu S; Weinstein S; Nisenbaum H; Fox K; Pasha T; Zhang P; Araujo L; Carver J; Czerniecki BJ
Am J Surg; 2009 Oct; 198(4):488-94. PubMed ID: 19800453
[TBL] [Abstract][Full Text] [Related]
5. Development of vaccines for high-risk ductal carcinoma in situ of the breast.
Czerniecki BJ; Roses RE; Koski GK
Cancer Res; 2007 Jul; 67(14):6531-4. PubMed ID: 17638860
[TBL] [Abstract][Full Text] [Related]
6. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
7. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
8. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
9. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
Shekhar MP; Kato I; Nangia-Makker P; Tait L
Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
11. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
12. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
14. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
15. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
16. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S
Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508
[TBL] [Abstract][Full Text] [Related]
17. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
Storm FK; Gilchrist KW; Warner TF; Mahvi DM
Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
[TBL] [Abstract][Full Text] [Related]
18. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
19. Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101
[TBL] [Abstract][Full Text] [Related]
20. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER
Lowenfeld L; Zaheer S; Oechsle C; Fracol M; Datta J; Xu S; Fitzpatrick E; Roses RE; Fisher CS; McDonald ES; Zhang PJ; DeMichele A; Mick R; Koski GK; Czerniecki BJ
Oncoimmunology; 2017; 6(9):e1207032. PubMed ID: 28932627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
